195 related articles for article (PubMed ID: 23774257)
1. Retention of structure, antigenicity, and biological function of pneumococcal surface protein A (PspA) released from polyanhydride nanoparticles.
Haughney SL; Petersen LK; Schoofs AD; Ramer-Tait AE; King JD; Briles DE; Wannemuehler MJ; Narasimhan B
Acta Biomater; 2013 Sep; 9(9):8262-71. PubMed ID: 23774257
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation into amphiphilic polyanhydride microparticles stabilizes Yersinia pestis antigens.
Carrillo-Conde B; Schiltz E; Yu J; Chris Minion F; Phillips GJ; Wannemuehler MJ; Narasimhan B
Acta Biomater; 2010 Aug; 6(8):3110-9. PubMed ID: 20123135
[TBL] [Abstract][Full Text] [Related]
3. The effect of polyanhydride chemistry in particle-based cancer vaccines on the magnitude of the anti-tumor immune response.
Wafa EI; Geary SM; Goodman JT; Narasimhan B; Salem AK
Acta Biomater; 2017 Mar; 50():417-427. PubMed ID: 28063991
[TBL] [Abstract][Full Text] [Related]
4. Cellular Internalization Mechanisms of Polyanhydride Particles: Implications for Rational Design of Drug Delivery Vehicles.
Phanse Y; Lueth P; Ramer-Tait AE; Carrillo-Conde BR; Wannemuehler MJ; Narasihan B; Bellaire BH
J Biomed Nanotechnol; 2016 Jul; 12(7):1544-52. PubMed ID: 29337493
[TBL] [Abstract][Full Text] [Related]
5. Room Temperature Stable PspA-Based Nanovaccine Induces Protective Immunity.
Wagner-Muñiz DA; Haughney SL; Kelly SM; Wannemuehler MJ; Narasimhan B
Front Immunol; 2018; 9():325. PubMed ID: 29599766
[No Abstract] [Full Text] [Related]
6. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
[TBL] [Abstract][Full Text] [Related]
7. Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.
Yamamoto M; McDaniel LS; Kawabata K; Briles DE; Jackson RJ; McGhee JR; Kiyono H
Infect Immun; 1997 Feb; 65(2):640-4. PubMed ID: 9009325
[TBL] [Abstract][Full Text] [Related]
8. Structural and antigenic stability of H5N1 hemagglutinin trimer upon release from polyanhydride nanoparticles.
Ross KA; Loyd H; Wu W; Huntimer L; Wannemuehler MJ; Carpenter S; Narasimhan B
J Biomed Mater Res A; 2014 Nov; 102(11):4161-8. PubMed ID: 24443139
[TBL] [Abstract][Full Text] [Related]
9. Intranasal immunization with pneumococcal surface protein A in the presence of nanoparticle forming polysorbitol transporter adjuvant induces protective immunity against the Streptococcus pneumoniae infection.
Kye YC; Park SM; Shim BS; Firdous J; Kim G; Kim HW; Ju YJ; Kim CG; Cho CS; Kim DW; Cho JH; Song MK; Han SH; Yun CH
Acta Biomater; 2019 May; 90():362-372. PubMed ID: 30922953
[TBL] [Abstract][Full Text] [Related]
10. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae.
Kong IG; Sato A; Yuki Y; Nochi T; Takahashi H; Sawada S; Mejima M; Kurokawa S; Okada K; Sato S; Briles DE; Kunisawa J; Inoue Y; Yamamoto M; Akiyoshi K; Kiyono H
Infect Immun; 2013 May; 81(5):1625-34. PubMed ID: 23460513
[TBL] [Abstract][Full Text] [Related]
11. High throughput cell-based screening of biodegradable polyanhydride libraries.
Adler AF; Petersen LK; Wilson JH; Torres MP; Thorstenson JB; Gardner SW; Mallapragada SK; Wannemuehler MJ; Narasimhan B
Comb Chem High Throughput Screen; 2009 Aug; 12(7):634-45. PubMed ID: 19531023
[TBL] [Abstract][Full Text] [Related]
12. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
[TBL] [Abstract][Full Text] [Related]
13. Polymer chemistry influences monocytic uptake of polyanhydride nanospheres.
Ulery BD; Phanse Y; Sinha A; Wannemuehler MJ; Narasimhan B; Bellaire BH
Pharm Res; 2009 Mar; 26(3):683-90. PubMed ID: 18987960
[TBL] [Abstract][Full Text] [Related]
14. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA.
Briles DE; Hollingshead SK; King J; Swift A; Braun PA; Park MK; Ferguson LM; Nahm MH; Nabors GS
J Infect Dis; 2000 Dec; 182(6):1694-701. PubMed ID: 11069242
[TBL] [Abstract][Full Text] [Related]
15. Effect of polymer chemistry and fabrication method on protein release and stability from polyanhydride microspheres.
Lopac SK; Torres MP; Wilson-Welder JH; Wannemuehler MJ; Narasimhan B
J Biomed Mater Res B Appl Biomater; 2009 Nov; 91(2):938-947. PubMed ID: 19642209
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary dry powder vaccine of pneumococcal antigen loaded nanoparticles.
Kunda NK; Alfagih IM; Miyaji EN; Figueiredo DB; Gonçalves VM; Ferreira DM; Dennison SR; Somavarapu S; Hutcheon GA; Saleem IY
Int J Pharm; 2015 Nov; 495(2):903-12. PubMed ID: 26387622
[TBL] [Abstract][Full Text] [Related]
17. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
[TBL] [Abstract][Full Text] [Related]
18. PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice.
Briles DE; King JD; Gray MA; McDaniel LS; Swiatlo E; Benton KA
Vaccine; 1996 Jun; 14(9):858-67. PubMed ID: 8843627
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins.
Miyaji EN; Vadesilho CF; Oliveira ML; Zelanis A; Briles DE; Ho PL
Clin Vaccine Immunol; 2015 Feb; 22(2):213-20. PubMed ID: 25520146
[TBL] [Abstract][Full Text] [Related]
20. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
